ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07576
0,00%
Bitcoin
64.189,30
0,30%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Viridian Therapeutics Inc (VRDN)

  7. Viridian Therapeutics Inc (VRDN) News

VRDN Viridian Therapeutics Inc

16,30
1,72 (11,80%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Viridian Therapeutics Inc VRDN NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
1,72 11,80% 16,30 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
15,08 15,01 15,50 15,40 14,58
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
03.5.202414:00BWViridian Therapeutics Announces Inducement Grants Under..
29.4.202414:00BWViridian Therapeutics to Webcast First Quarter 2024..
04.4.202422:01BWViridian Therapeutics Announces Inducement Grants Under..
06.3.202422:01BWViridian Therapeutics Announces Inducement Grants Under..
05.3.202414:00BWViridian Therapeutics to Participate in the Leerink Partners..
28.2.202422:10EDGAR2Form S-8 - Securities to be offered to employees in employee..
27.2.202422:07EDGAR2Form 8-K - Current report
27.2.202422:01BWViridian Therapeutics Highlights Recent Progress and Reports..
16.2.202414:00BWViridian Therapeutics Appoints Jennifer Tousignant as Chief..
15.2.202402:28EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202422:08EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202422:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202422:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
14.2.202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.2.202415:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07.2.202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.2.202422:01BWViridian Therapeutics Announces Inducement Grant Under..
25.1.202400:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.1.202423:12EDGAR2Form SC 13D/A - General statement of acquisition of..
19.1.202423:22EDGAR2Form 8-K - Current report
19.1.202422:32EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18.1.202404:00BWViridian Therapeutics Announces Pricing of Public Offering..
17.1.202422:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
17.1.202422:01BWViridian Therapeutics Announces Proposed Underwritten Public..
12.1.202422:31EDGAR2Form 3 - Initial statement of beneficial ownership of..
08.1.202414:08EDGAR2Form 8-K - Current report
08.1.202414:00BWViridian Therapeutics to Present Key 2024 Corporate..
04.1.202414:00BWViridian Therapeutics to Webcast Presentation at the 42nd..
18.12.202317:45EDGAR2Form 144 - Report of proposed sale of securities
18.12.202314:15EDGAR2Form 8-K - Current report
18.12.202313:00BWViridian Therapeutics Announces Positive Clinical Data in..
12.12.202322:19EDGAR2Form 144 - Report of proposed sale of securities
08.12.202322:17EDGAR2Form SC 13G - Statement of acquisition of beneficial..
07.12.202322:22EDGAR2Form 144 - Report of proposed sale of securities
01.12.202322:04EDGAR2Form 144 - Report of proposed sale of securities
30.11.202322:05EDGAR2Form S-3ASR - Automatic shelf registration statement of..
21.11.202314:00BWViridian Therapeutics to Participate in 6th Annual Evercore..
13.11.202323:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.11.202322:28EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13.11.202322:01BWViridian Therapeutics Reports Third Quarter 2023 Financial..
08.11.202314:00BWViridian Therapeutics to Participate in the Jefferies London..
03.11.202321:30EDGAR2Form SC 13D/A - General statement of acquisition of..
03.11.202313:00BWViridian Therapeutics Announces Encore Presentations at the..
02.11.202302:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.11.202321:40EDGAR2Form 3 - Initial statement of beneficial ownership of..
01.11.202321:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.11.202321:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.11.202321:30EDGAR2Form 3 - Initial statement of beneficial ownership of..
30.10.202313:35EDGAR2Form 8-K - Current report
30.10.202313:30BWViridian Therapeutics Appoints New Chief Executive Officer,..

Kürzlich von Ihnen besucht

NASDAQ
VRDN
Viridian Therapeutics
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten